Neurocrine Corp (NBIX) - Market Value to Book Value Ratio
Dominance in the nerve disorder therapy niche protects Neurocrine Biosciences (NBIX) margins from price declines. Patented formulas ensure stable demand, creating a high-yield profit generator. The chronic nature of the diseases guarantees a long implementation cycle. The change in the revaluation level of balance sheet capital in the intraday dynamics on the GURU.Markets chart shows that the current value is 3.99, capturing the market value of net assets.
Neurocrine (NBIX) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization indicators:
- book capitalization data:
- debt and solvency information:
Debt to Equity Neurocrine Biosciences|NBIX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Neurocrine Biosciences Inc|NBIX - Company Cumulative Debt|Debt to Book Capitalization Ratio Neurocrine Biosciences Inc|NBIX - Company Long-Term Indebtedness|Company Short-Term Debts Neurocrine Biosciences|Quick Liquidity Indicator neurocrine.com
- earnings and valuation multiples indicators:
Comprehensive company analysis:Neurocrine Biosciences
This ratio is calculated as the quotient of the current market value of all shares divided by the net asset value, determining the actual margin of safety for the investment. By analyzing the price-to-book ratio of Neurocrine Biosciences (NBIX), an investor assesses the risk of overpaying for the company's high scientific reputation in neurology to avoid critical losses during a price correction.
Key competitors
BIIB (Biogen Inc.) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio RGC|Market Value to Book Value Ratio Axsome Therapeutics, Inc.|Capitalization to Book Value Ratio ACAD (ACADIA Pharma)|Market Capitalization to Book Value Ratio XENE|VKTX - Market-to-Book Ratio|Supernus Pharmaceuticals - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio catalystpharma.com CPRX|DNLI - Market Value to Book Value Ratio|Market Value to Book Value HRMY (Harmony Biosciences Inc)|Biohaven Pharmaceutical (BHVN) - Market Value to Book Value Ratio|Market-to-Book Ratio Amylyx Corp (AMLX)|Market Value to Book Value Ratio Trevi Therapeutics|Capitalization to Book Value Ratio PRAX (praxismedicines.com)|Market Capitalization to Book Value Ratio AVXL|CBLL - Market-to-Book Ratio|prothena.com - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Alector Inc. ALEC|ANNX - Market Value to Book Value Ratio|Market Value to Book Value OMER (Omeros Corporation)|Neurogene (NGNE) - Market Value to Book Value Ratio|Market-to-Book Ratio AC Immune S.A. (ACIU)|VYGR (Voyager Pharma) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Neumora Corp (NMRA)|Market Value to Book Value Ratio Scilex Holding Company (SCLX)|TVGN (tevogen.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio ACOG (Alpha Cognition Inc.)|Market Capitalization to Book Value cogrx.com (CGTX)|IKT - Market Value to Book Value Ratio|SAVA (Cassava Pharma) - Capitalization to Book Value Ratio|ASRT: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Coya Therapeutics (COYA)|Market Cap to Net Assets Ratio VTGN|OVID: Market Value to Book Value|Market Capitalization to Book Value Ratio ABOS|Market Value to Book Value Ratio CRVO (CervoMed Corporation)|Market Capitalization to Book Value Ratio ATHE (Alterity Therapeutics Limited)|Market Capitalization to Book Value Clene Inc (CLNN)|PEPG - Market Value to Book Value Ratio|Market-to-Book Ratio jupiterneurosciences.com|Relmada (RLMD) - Market Value to Book Value Ratio|ANVS - Market Capitalization to Book Value|GRCE (Grace Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio fireflyneuro.com (AIFF)|Market Capitalization to Book Value Ratio KLTO|Market Capitalization to Book Value neurosense-tx.com|Market Capitalization to Book Value Ratio RVPH (Reviva Pharmaceuticals Holdings)|MetaVia Inc. (MTVA) - Market-to-Book Ratio|NRXS - Market Value to Book Value Ratio|HSDT (Helius Medical) - Capitalization to Book Value Ratio|PASG: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Neuphoria Therapeutics|NERV (Minerva Neurosciences Corp) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Athira Pharma Corp ATHA|Market Value to Book Value Ratio Addex Therapeutics (ADXN)|Market Capitalization to Book Value alzamend.com|Market Value to Book Value Ratio Cyclerion Therapeutics, Inc. CYCN|PTIX: Capitalization to Book Value Ratio|Pasithea - Market Capitalization to Book Value Ratio|CRGT: Market Value to Book Value Ratio|ATXI: Market Capitalization to Book Value Ratio|BCLI - Market Capitalization to Book Value|Market Cap to Net Assets Ratio CARA|Capitalization to Book Value Ratio CHRO (Chromocell Therapeutics Corp)|Market Value to Book Value Ratio Eliem Therapeutics (ELYM)|intracellulartherapies.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio LBPH (Longboard Pharmaceuticals)|marinuspharma.com (MRNS) - Market-to-Book Ratio|NKGN: Market Cap to Net Assets Ratio|NRBO - Market Capitalization to Book Value Ratio|Sage Therapeutics, Inc (SAGE) - Market Value to Book Value Ratio|Synaptogenix, Inc - Market Value to Book Value|Market Value to Book Value Ratio Trevena, Inc.|Market-to-Book Ratio Vigil Neuro VIGL|Market Value to Book Value Ratio Anew Medical, Inc. (WENA)|Cerevel Therapeutics Inc - Capitalization to Book Value Ratio